Champions Oncology, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $69.7M
- Price
- $5.01
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.80%
- Volume
- 16.3K
About
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Quick stats
Shares outstanding13.9M
Computed float5.1M
Float / shares36.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000771856
AI Summary
AI-generated1/14
standardbullishearnings
Champions Oncology Reports Revenue of $15.2 Million
Champions Oncology posted fiscal Q1 2027 (quarter ended July 31, 2026) oncology revenue of $15.2 million, up 8.8% year over year, driven by better conversion of contracted research services work and higher data license revenue.
Profitability inflected: oncology services margin expanded to 51% from 43%, and Adjusted EBITDA swung to $671,000 from $59,000 a year ago, which management attributed to operating leverage as revenue scales.
The GAAP net loss narrowed to $426,000 from $466,000, with non-GAAP adjusted EPS of $0.05 versus $0.01; sales and marketing spend jumped 66.6% to $3.1 million as the company builds out its commercial organization and radiopharmaceutical capabilities.
Champions ended the quarter with roughly $4.4 million in cash, no debt, and about $492,000 of operating cash use — a thin liquidity cushion relative to its expense base.
Red flags
- Cash fell to $4.4 million (from $10.3 million a year ago) with ~$492,000 quarterly operating cash use — limited liquidity cushion
- Sales and marketing expense up 66.6% YoY on commercial buildout, ahead of the 8.8% revenue growth
- No forward guidance provided in the release